REGEnLIFE, a French company specialising in the research and development of innovative neurostimulation technologies for the prevention and treatment of neurodegenerative diseases, announces the expansion of its pivotal clinical trial for Alzheimer’s disease, Light4Life, with the opening of two new hospital centres in Paris: one at Lariboisière Hospital and the other at Broca Hospital.
Alzheimer’s disease is a complex, multifactorial condition. It is caused by the accumulation of two toxic proteins in the brain: beta-amyloid and tau proteins. Other abnormalities in brain function are also observed there.
However, its cause is not yet known. Furthermore, there is still a great deal of diagnostic uncertainty, and there are still no treatments available to halt the progression of the disease.
Against this backdrop, and following the initial launch in partnership with Toulouse University Hospital in September 2023 and the opening of two further centres in Occitanie, in Lavaur and Castres, these new sites in Paris are expected to speed up the recruitment of 108 patients aged between 55 and 85 with mild to moderate Alzheimer’s disease.
This study is being led by the principal investigator, Dr Julien Delrieu, who will be joined by new investigators, recognised specialists in Alzheimer’s disease, Professor Claire Paquet and Dr Marie-Laure Seux.
« “The ongoing pivotal clinical trial represents a major step forward in exploring new therapeutic strategies for Alzheimer’s disease. By targeting both the brain and the gut, this innovative approach could bring about lasting improvements in the management of the disease, ” explains Dr Julien Delrieu, a neurogeriatrician at Toulouse University Hospital.
He added: “The aim is to assess its effect on the progression of symptoms and patients’ quality of life, with a view to offering a complementary alternative to existing treatments.”
Today, we have a reliable but late-stage diagnostic method for the disease. Current treatments alleviate symptoms but do not alter the course of the disease, which affects 900,000 people in France and sees 225,000 new cases diagnosed each year.
